North Shore Collaborative Therapy Psychologist - Clinical Medicare: Medicare Enrolled Practice Location: 66-892 Wanini St, Waialua, HI 96791 Phone: 808-457-1311 Fax: 808-457-1311 |
Bliss Matters, Llc Marriage & Family Therapist Medicare: Not Enrolled in Medicare Practice Location: 67-632 Kane Pl, Waialua, HI 96791 Phone: 808-628-0020 |
Keiki Educational Consultants, Inc. Behavioral Analyst Medicare: Not Enrolled in Medicare Practice Location: 67-216 Niumaloo Pl, Waialua, HI 96791 Phone: 808-298-2658 Fax: 808-637-5960 |
Nancy K L Delamarter Social Worker - Clinical Medicare: Not Enrolled in Medicare Practice Location: 68-180 Au St Apt B, Waialua, HI 96791 Phone: 808-351-5311 Fax: 808-441-1965 |
Carrie Cochran, Mft Llc Marriage & Family Therapist Medicare: Not Enrolled in Medicare Practice Location: 66-216 Farrington Hwy, Waialua, HI 96791 Phone: 808-542-3030 |
News Archive
Annual respiratory epidemics are thought to result in 250,000 to 500,000 deaths every year, around the world. Therefore the pressure on laboratories to choose a respiratory assay that allows early, efficient and accurate patient diagnosis is crucial.
A small compound called an aptamer that specifically targets and stimulates a human immune cell can greatly increase the effectiveness of an immunotherapeutic drug designed to destroy malignant or virus-infected cells. The development of a novel apatamer that recognizes activated T-lymphocytes and can boost the therapeutic effect of cell-based vaccines is described in an article in Nucleic Acid Therapeutics, a peer-reviewed journal from Mary Ann Liebert, Inc. publishers.
Researchers comparing leading treatment approaches for patients with severe uveitis have discovered that systemic therapy with oral corticosteroids and immunosuppression can preserve or improve vision in the long term better than regional implant therapy can.
A unique collaboration among physician-scientists at Memorial Sloan-Kettering Cancer Center has yielded the most comprehensive genomic analysis of prostate cancer to date. "Genomic studies in other cancer types have resulted in new drug targets and strategies to classify patients into clinically meaningful subgroups that improve treatment decisions," said senior study author Charles Sawyers, Chair of the Human Oncology and Pathogenesis Program at MSKCC and a HHMI investigator. "This first -ever database of its type brings us one step closer to achieving that goal in prostate cancer."
Results from the largest prospective controlled ulcerative colitis (UC) trial conducted to date, called the QD dosing investigation for efficacy IN UC maintenance (QDIEM), found that once-daily dosing of Asacol(R) (mesalamine) delayed-release 400 mg tablets at 1.6-2.4 g/day was comparable to twice-daily dosing for the maintenance of remission in patients with UC.
› Verified 3 days ago